SAIL-66
- Generic Name
- SAIL-66
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 231
- Registration Number
- NCT05735366
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸MUSC Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath